A Nielsen alternative (or NielsenIQ alternative) is a primary-research firm you brief when the retail measurement dashboard cannot show how a brand stacks up in named accounts, traditional trade, or SKU-level cuts in-market. BioNixus fields that study across MENA and 48 countries — project-priced, no enterprise retail-audit minimum. Keep NielsenIQ for national retail / FMCG measurement. Brief us for the cut the feed misses.
Founded in 2012 and headquartered in Sheridan, Wyoming, with regional leadership offices in London and Cairo and field offices in Dubai, Al Khobar and Kuwait City. Latin America is covered from the US office with a network of local consultants. BioNixus is in the process of opening a São Paulo office by the end of 2026. Account-level and SKU-level primary research, pharmacy and hospital fieldwork, HCP and shopper studies, and competitive intelligence — without an enterprise retail-audit contract. See account-level market research, pricing, and the IQVIA alternative.
“BioNixus delivered payer and hospital research across the GCC with the depth we needed for launch sequencing.”
Published client review · bionixus.com/client-reviews
Anyone typing “Nielsen alternative,” “NielsenIQ competitors,” or “companies like Nielsen” is usually buying one of these briefs: a brand or category team that already pays for NielsenIQ RMS and still cannot see named accounts, traditional trade, or SKU cuts; an OTC / consumer-health team that needs pharmacy and shopper primary beyond modern-trade panels; a pharma affiliate that needs HCP, payer, or hospital evidence NielsenIQ was never built to sell; or a mid-market team that cannot clear an enterprise retail-data contract for a single-country question.
None of that makes NielsenIQ a bad choice — for national modern-trade sales, pricing, distribution, and promotion tracking across FMCG and OTC in markets like UAE and KSA, it is often the right one. It does mean “Nielsen or nothing” is the wrong frame. BioNixus is the primary-research complement, not a cheaper clone of NielsenIQ RMS.
| Company | Regional strength | Core product | Minimum engagement | Best for |
|---|---|---|---|---|
| NielsenIQ | Global RMS; MENA often via a regional hub. | Retail Measurement Services, FMCG / OTC category tracking, modern-trade POS share. | Enterprise syndicated subscription; not publicly disclosed. | National modern-trade sales, pricing, distribution, and promotion tracking. |
| IQVIA | Global syndicated healthcare audits; MENA via hubs. | Pharma audits, real-world evidence, CRO — not an FMCG retail panel. | Enterprise-scale; not publicly disclosed. | National hospital / pharmacy audit sizing. See IQVIA alternative. |
| Kantar | Global brand-track network; GCC via Dubai. | Brand tracking, Marketplace, large-scale consumer panels. | Network-scale tracker contracts; not disclosed. | Brand and shopper attitude — not named-account offtake. |
| Euromonitor | Syndicated Passport desk coverage. | Category sizing and competitive landscapes. | Report and database subscription. | Desk estimates, not in-country fieldwork. |
| Ipsos | Offices in Riyadh, Jeddah, Dubai and a wider global network. | Custom U&A, brand, and public-affairs studies. | Large-agency project scale; not disclosed. | Custom consumer studies at agency scale. |
| BioNixus | 48 countries — MENA/GCC with a Cairo office; US and UK presence. | ✓ Primary fieldwork: account-level, SKU-level, traditional trade, HCP, pharmacy, shopper. | ✓ No enterprise retail-audit minimum; project- and country-based. | The cut NielsenIQ RMS cannot sell — named accounts, traditional trade, SKU, HCP/payer/hospital. |
Where a cell says “not disclosed,” that reflects the absence of public information — not an estimate. Ask any shortlisted vendor directly for current pricing, minimums, and timelines. Being listed here is not an attack on NielsenIQ.
| Capability | BioNixus | NielsenIQ |
|---|---|---|
| National retail / FMCG share | Complement via primary — not a national RMS feed | ✓ Core RMS product |
| Modern-trade POS | Fielded cuts in named banners | ✓ Core RMS strength |
| Traditional trade | ✓ Core fieldwork | Typically undersampled or excluded |
| Account-level | ✓ Named accounts | National / modern-trade cuts |
| SKU-level | ✓ In-market SKU cuts | Category / national more than a named SKU |
| HCP / payer / KOL | ✓ Core primary | Not built as a healthcare primary house |
| Hospital / Rx clinical | ✓ Pharmacy and hospital fieldwork | Not the RMS product |
| Contract model | ✓ Project / country — no enterprise RMS minimum | Syndicated subscription |
| Typical client need | The gap beside the dashboard | National modern-trade measurement |
Five reasons commercial teams add primary research beside RMS — not instead of it.
NielsenIQ RMS is the right buy for national retail / FMCG / modern-trade measurement. Do not cancel it to “replace Nielsen.” Brief BioNixus for the account-level, SKU-level, or traditional-trade cut the feed cannot produce — then keep both on the insights stack.
BioNixus does not sell a second retail-measurement subscription. We field a scoped study: named accounts, SKUs, cities, and channels. The deliverable is primary evidence for a commercial decision, not another national share curve.
In MENA and many emerging markets, bakals, wholesalers, and open markets still move volume that modern-trade panels undersample or exclude. Primary fieldwork is how you see that channel — not a dashboard filter NielsenIQ never sold you.
OTC teams often already pay for NielsenIQ. Pharma and MedTech affiliates still need HCP, payer, KOL, pharmacy, and hospital evidence. That is a different product. Keep RMS for the consumer-health shelf; brief BioNixus for the clinical and access cut. For syndicated healthcare audits, see the IQVIA alternative.
NielsenIQ is structured around syndicated retail-data contracts. BioNixus prices by project and country — typical 2026 bands custom research from $10,000 to $60,000 ($10k–$60k). See pricing. You do not need an enterprise RMS minimum to ask one country, one brand, one account list.
You need standardized modern-trade retail measurement across many countries; the category is FMCG or OTC and the panel covers your channels; the question is national share, pricing, distribution, or promotion — not a named account; or you already have RMS and the feed answers the brief.
The brief names accounts, SKUs, or traditional trade; you need pharmacy, shopper, HCP, payer, or hospital evidence; a mid-market team cannot clear an enterprise retail-data contract for a single-country question; or you already pay for NielsenIQ and still cannot see the cut.
Smart default: run both. Treating this as “Nielsen or nothing” usually is not necessary. Keep NielsenIQ for national modern-trade measurement. Add BioNixus for the primary cut the feed misses.
You already buy NielsenIQ for modern-trade OTC share and still need pharmacy mystery shopping, shopper work, or traditional-trade cuts the panel does not sell.
You need HCP, payer, or hospital evidence NielsenIQ was never built to sell — and you may already keep IQVIA for the audit. BioNixus fields the primary study.
A single-country question should not require an enterprise retail-data contract. Project-priced fieldwork covers the accounts and SKUs you can name.
You need a primary-research partner beside a NielsenIQ or IQVIA subscription your client already holds — without pitching a rip-and-replace.
BioNixus is a global firm with the same operating map as the IQVIA comparison page:
US headquarters at 1309 Coffeen Avenue STE 1200, Sheridan, Wyoming 82801. BioNixus supports US brand and commercial teams that already buy NielsenIQ and still need account-level or traditional-trade fieldwork in-market.
US phone: +1 888 465 5557
London office serving UK and European teams. Research under MHRA-aligned and ICH-GCP protocols, with GDPR-compliant data handling throughout.
UK phone: +44 7727 666682
Regional headquarters in Cairo, Egypt, with established field infrastructure across Saudi Arabia, UAE, Kuwait, Egypt, Qatar, Bahrain, and Oman. GCC presence includes Dubai, Al Khobar, and Kuwait City. BioNixus has operated across MENA since 2012.
European market research support alongside MENA depth, and Latin America is covered from the US office with a network of local consultants. BioNixus is in the process of opening a São Paulo office by the end of 2026. Same operating map as the IQVIA alternative page.
A Nielsen alternative (or NielsenIQ alternative) is a primary-research firm you brief when the retail measurement dashboard cannot show how a brand stacks up in named accounts, traditional trade, or SKU-level cuts in-market. BioNixus fields that study across MENA and 48 countries — project-priced, with no enterprise retail-audit minimum. Keep NielsenIQ for national retail / FMCG measurement. Brief us for the cut the feed misses.
No. Complementary. Keep NielsenIQ for national retail / FMCG / modern-trade measurement. Brief BioNixus for account-level, SKU-level, traditional trade, and HCP/payer/hospital work NielsenIQ was never built to sell. The smart default is to run both.
NielsenIQ’s strength in those markets is FMCG and OTC retail measurement in modern trade. It is not a substitute for HCP, payer, hospital, or Rx clinical primary research. Pharma affiliates who already buy NielsenIQ for consumer-health still brief BioNixus for the healthcare cut.
Syndicated retail and pharma audits are built for national or panel-modelled category share. Named accounts, traditional trade, and SKU-level in-market cuts are a different product — primary fieldwork, not another dashboard row. See account-level market research and the IQVIA alternative page for the healthcare audit side.
Yes. That is the smart default. Run NielsenIQ for national modern-trade measurement and BioNixus for the account, SKU, or traditional-trade study the feed cannot produce. It is not an either/or switch.
NielsenIQ subscription fees are not public. BioNixus prices by project and country. Typical 2026 bands: custom research from $10,000 to $60,000 ($10k–$60k). See /pricing. No enterprise retail-audit contract is required to start. A scoped proposal is ready within 48 hours of a brief.
Buyers comparing NielsenIQ usually also look at IQVIA (pharma audits), Kantar (brand-track), Euromonitor (desk category sizing), Ipsos (custom consumer), and regional primary-research firms such as BioNixus. None of those replace RMS for national modern-trade measurement. BioNixus competes for the primary-research brief the dashboard does not cover.
They measure different things. NielsenIQ RMS is the right quality bar for national modern-trade POS and category tracking. BioNixus collects primary fieldwork — account-level, SKU-level, traditional trade, pharmacy, HCP, and hospital evidence — with source traceability to the study design. Do not score them on a single “data quality” axis.